In just three months, 23andMe’s Myeloproliferative Neoplasms (MPN) Research Initiative has grown to more than 330 active participants. Our Scientific Advisory Board has grown as well with another prestigious scientist, Dr. Ruben Mesa, joining Dr. Jason Gotlib and Dr. James Zehnder from the Stanford University School of Medicine and Stanford Cancer Institute.
Dr. Mesa serves as Director of the Acute and Chronic Leukemia Program and as Chair of the Division of Hematology & Medical Oncology at the Mayo Clinic. In addition to his work at the Mayo Clinic, Dr. Mesa is also Vice Chair of the Myeloproliferative Disorders Research Consortium based in New York. His work focuses on advancing the understanding and therapy of the chronic forms of these kinds of cancers. We are extremely excited to welcome Dr. Mesa to our MPN Scientific Advisory Board.
To read more about this announcement, please click here for the press release.
Collaboration is the best way to offer hope and a future to individuals affected by rare cancers such as MPN. We look forward to working with our participants and our advisors* to see what type of research advancements we can achieve together.
Learn more at www.23andme.com/mpn.
*MPN Science Advisory Board members receive no compensation from 23andMe.